मूलभूत आँकड़े
| LEI | 549300PCOT1RLQ23DL21 |
| CIK | 744452 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Applied DNA Sciences, Inc., Warrants
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 App |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| August 14, 2025 |
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results Exhibit 99.1 Applied DNA Reports Third Quarter Fiscal 2025 Financial Results STONY BROOK, N.Y. – August 14, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended |
|
| July 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Applied DNA Sciences, Inc. |
|
| July 25, 2025 |
Exhibit 3.1 CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. a Delaware corporation The undersigned, for the purpose of forming a corporation pursuant to the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: ARTICLE I The name of this corporation is Applied DNA Sciences, Inc. ARTICLE II The address of its registered office in the State of |
|
| July 25, 2025 |
As filed with the Securities and Exchange Commission on July 24, 2025 As filed with the Securities and Exchange Commission on July 24, 2025 Registration No. |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| June 30, 2025 |
Exhibit 99.1 Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx - Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth - STONY BROOK, N.Y. – June 30, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in PCR-based DNA technologies, announced a |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 17, 2025 |
Exhibit 99.1 Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward - President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO - STONY BROOK, N.Y. – June 17, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. |
|
| June 17, 2025 |
Exhibit 10.1 Executive Officer Separation Agreement THIS EXECUTIVE OFFICER SEPARATION AGREEMENT (the “Separation Agreement”) is made and entered into and is effective as of this 16th day of June, 2025 (the “Effective Date”) by and between Applied DNA Sciences, Inc. (herein the “Employer” or “Company”) and Dr. James A. Hayward (herein “Employee”) and for good and valuable consideration including th |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 29, 2025 |
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 Exhibit 99.1 Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 STONY BROOK, N.Y. – May 29, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12 |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 29, 2025 |
Form of Eighth Certificate of Amendment to the Certificate of Incorporation. Exhibit 3.1 PROPOSED FORM OF CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: FIRST: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incorporation”), of th |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 15, 2025 |
Exhibit 99.1 Applied DNA Reports Second Quarter Fiscal 2025 Financial Results - Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET - STONY BROOK, N.Y. – May 15, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 Ap |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| April 4, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| March 12, 2025 |
Form of Seventh Certificate of Amendment to the Certificate of Incorporation Exhibit 3.1 SEVENTH CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: FIRST: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incorporation”), of the Corpora |
|
| March 12, 2025 |
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025 Exhibit 99.1 Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025 STONY BROOK, N.Y. – March 12, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| February 28, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| February 14, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 |
|
| February 13, 2025 |
Exhibit 99.1 Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress - Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified for Commercial Operation in January - - Webcast and Conference Call Scheduled for today a |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 30, 2025 |
Letter from Marcum dated January 30, 2025 Exhibit 16.1 January 30, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Applied DNA Sciences, Inc. under Item 4.01 of its Form 8-K dated January 30, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Applied DNA Sciences, I |
|
| January 23, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 17, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-283315 PROSPECTUS Up to 20,312,500 shares of Common Stock underlying the Series C Warrants Up to 20,312,500 shares of Common Stock underlying the Series D Warrants Up to 1,015,625 shares of Common Stock underlying the Placement Agent Warrants Applied DNA Sciences, Inc. This prospectus relates to the resale from time to time, by the se |
|
| January 15, 2025 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 January 15, 2025 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 January 15, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed November 19, 2024, as amended File No. 333-283315 Ladies and Gentlemen: Pursuant to Rule 461 under the Secu |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 13, 2025 |
Exhibit 99.1 ©2025 Applied DNA Sciences, Inc. Empowering the Genetic Medicines Revolution Nasdaq: APDN January 2025 ©2025 Applied DNA Sciences, Inc. 2 The statements made by Applied DNA in this presentation may be “forward - looking” in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of 1934 and the Private Securities Litigation |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025. As filed with the Securities and Exchange Commission on January 10, 2025. Registration Statement No. 333-283315 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdict |
|
| December 17, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 APPLIED DN |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| December 17, 2024 |
Exhibit 99.1 Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines - Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Buildout of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference |
|
| December 17, 2024 |
Exhibit 97.1 Applied DNA Sciences, Inc. (the “Company”) Compensation Clawback Policy Effective Date: October 2, 2023 1. Purpose. The Company has adopted this Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, and Nasdaq Listing Rule 5608, which require the recovery of certain forms of executive |
|
| December 17, 2024 |
Exhibit 19.1 APPLIED DNA INSIDER TRADING POLICY Purpose The purpose of this Insider Trading Policy is to define those individuals who are designated as “insiders” for the purpose of APDN stock trading restrictions and to outline the obligations of insiders regarding insider trading and federal securities laws. Except where otherwise explicitly stated, this insider trading policy applies to all emp |
|
| December 17, 2024 |
Subsidiaries of Applied DNA Sciences, Inc. Exhibit 21.1 SUBSIDIARIES OF APPLIED DNA SCIENCES, INC. Subsidiary State or Country of Incorporation APDN (B.V.I.) Inc. British Virgin Islands Applied DNA Sciences Europe Limited United Kingdom Applied DNA Sciences India Private Limited India LineaRX, Inc. Delaware Applied DNA Clinical Labs LLC Delaware Spindle Biotech, Inc. Canada |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| November 19, 2024 |
Exhibit 3.2 BYLAWS OF APPLIED DNA SCIENCES, INC. TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF STOCKHOLDERS’ MEETINGS 2 2.5 MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE 3 2.6 QUORUM 3 2.7 ADJOURNED MEETING; NOTICE 3 2.8 ADMINISTRA |
|
| November 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) APPLIED DNA SCIENCES, INC. |
|
| November 19, 2024 |
As filed with the Securities and Exchange Commission on November 18, 2024. As filed with the Securities and Exchange Commission on November 18, 2024. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdiction of incorporat |
|
| November 14, 2024 |
EX-99.1 2 d834912dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value, of Applied DNA Sciences, Inc., a Delaware corp |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| November 14, 2024 |
APDN / Applied DNA Sciences, Inc. / Anson Funds Management LP - SC 13G Passive Investment SC 13G 1 d834912dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No.) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) APPLIED DNA SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03815U409 (CUSIP N |
|
| November 13, 2024 |
APDN / Applied DNA Sciences, Inc. / Grossman Bruce - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 eh24055609513ga1-adna.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied DNA Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03815U201 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the app |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| November 7, 2024 |
Certificate of Amendment to the Bylaws Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE BYLAWS OF APPLIED DNA SCIENCES, INC. FIRST: The Bylaws (“Bylaws”) of Applied DNA Sciences, Inc., a Delaware corporation (the “Corporation”) have been amended as follows: Section 2.6 of Article II of the Bylaws shall be amended and restated in its entirety to state as follows: “2.6 QUORUM. The holders of one-third of the stock issued and outstanding and e |
|
| October 31, 2024 |
Exhibit 99.1 Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement STONY BROOK, N.Y., - October 30, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Compa |
|
| October 31, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 30, 2024, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| October 31, 2024 |
Exhibit 10.3 WAIVER OF SUBSEQUENT EQUITY SALES PROVISION October 29, 2024 Reference is hereby made to Section 4(p) of that certain Placement Agency Agreement (the “Placement Agency Agreement”), dated May 28, 2024, by and among Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), Craig-Hallum Capital Group LLC (“Craig-Hallum”) and Laidlaw & Company (UK) Ltd. Capitalized terms used bu |
|
| October 31, 2024 |
Exhibit 10.2 AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT THIS AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of October 29, 2024, is by and between Applied DNA Sciences, Inc., a Delaware corporation (the "Company"), and the undersigned holder (the “Holder”). WHEREAS, pursuant to a Placement Agency Agreement, dated May 28, 2024, by and among the Company, Cr |
|
| October 31, 2024 |
Form of Series D Common Stock Purchase Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 31, 2024 |
Form of Series C Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 31, 2024 |
Form of Placement Agent Warrant Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 31, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| October 31, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272267 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2023) APPLIED DNA SCIENCES, INC. 19,247,498 Shares of Common Stock Pre-Funded Warrants to Purchase 1,065,002 Shares of Common Stock We are offering 19,247,498 shares of our common stock (the “Shares”) at a price of $0.32 per share to investors (the “Purchasers”) pursuant to this prospect |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| September 30, 2024 |
Exhibit 107 FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) Applied DNA Sciences, Inc. |
|
| September 30, 2024 |
As filed with the Securities and Exchange Commission on September 30, 2024 As filed with the Securities and Exchange Commission on September 30, 2024 Registration No. |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| September 18, 2024 |
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement STONY BROOK, N.Y., - September 18, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market |
|
| August 21, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 App |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| August 8, 2024 |
Exhibit 99.1 Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. – August 8, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The |
|
| August 5, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| August 2, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 28, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| June 21, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| June 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| June 7, 2024 |
SC 13G 1 shn13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Applied DNA Sciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03815U409 (CUSIP Number) May 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| June 7, 2024 |
SC 13G 1 l1cap13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Applied DNA Sciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03815U409 (CUSIP Number) May 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 29, 2024 |
Exhibit 4.3 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 29, 2024 |
Form of Placement Agent Warrant Exhibit 4.1 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| May 29, 2024 |
Exhibit 4.2 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockhold |
|
| May 29, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT May 28, 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agr |
|
| May 29, 2024 |
Exhibit 4.4 PREFUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 29, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-278890 Applied DNA Sciences, Inc. Up to 9,230,769 Units, Each Unit Consisting of One Share of Common Stock or One Pre-Funded Warrant to Purchase One Share of Common Stock, One Series A Warrant to Purchase One Share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock Placement Agent Warrants to Purchase Up to 461,538 S |
|
| May 29, 2024 |
Applied DNA Announces Pricing of $12 Million Public Offering Exhibit 99.1 Applied DNA Announces Pricing of $12 Million Public Offering STONY BROOK, N.Y., - May 28, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and othe |
|
| May 24, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 24, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 24, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 24, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockhol |
|
| May 24, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockhol |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 24, 2024 |
Exhibit 107 Registrant Name in English, if applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Fee Calculation Proposed Maximum or Carry Maximum Aggregate Amount of Security Security Forward Amount Offering Offering Registration Type Class Title Rule Registered Price Price(1) Fee Rate Fee (2) Fees to be Paid Equity Units, each consisting of: (i) one share of common stock, $0. |
|
| May 22, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 22, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 22, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 22, 2024 |
Form of Placement Agency Agreement Exhibit 10.50 PLACEMENT AGENCY AGREEMENT [], 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agrees |
|
| May 22, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 22, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 21, 2024 |
As filed with the Securities and Exchange Commission on May 21, 2024 As filed with the Securities and Exchange Commission on May 21, 2024 Registration No. |
|
| May 21, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 21, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 21, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 21, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 21, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Issuance Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 21, 2024 |
Exhibit 107 Registrant Name in English, if applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Fee Calculation Proposed Maximum or Carry Maximum Aggregate Amount of Security Security Forward Amount Offering Offering Registration Type Class Title Rule Registered Price Price(1) Fee Rate Fee (2) Fees Previously Paid Equity Units, each consisting of: (i) one share of common stock, $0. |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 16, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 May 16, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed April 24, 2024, as amended File No. 333-278890 Ladies and Gentle |
|
| May 15, 2024 |
Exhibit 4.14 PREFUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| May 15, 2024 |
Form of Placement Agent Warrant Exhibit 4.17 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| May 15, 2024 |
Exhibit 10.51 LOCK-UP AGREEMENT [], 2024 Craig-Hallum Capital Group LLC, acting as placement agent of the Offering (as defined below): Re: Offering (as defined below) by Applied DNA Sciences, Inc. (the “Company”) Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the closing of the Company’s offering of registered s |
|
| May 15, 2024 |
Form of Placement Agency Agreement Exhibit 10.50 PLACEMENT AGENCY AGREEMENT [], 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agrees |
|
| May 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Applied DNA Sciences, Inc. |
|
| May 15, 2024 |
Exhibit 3.1 CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. a Delaware corporation The undersigned, for the purpose of forming a corporation pursuant to the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: ARTICLE I The name of this corporation is Applied DNA Sciences, Inc. ARTICLE II The address of its registered office in the State of |
|
| May 15, 2024 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 15, 2024 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 15, 2024 |
As filed with the Securities and Exchange Commission on May 14, 2024 As filed with the Securities and Exchange Commission on May 14, 2024 Registration No. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 Ap |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2024 |
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results Exhibit 99.1 Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results STONY BROOK, N.Y. – May 10, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company’s Form 10-Q can be viewed at https://investors.adnas. |
|
| May 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2024 |
Cell - Free Enzymatic DNA Empowering the Genetic Medicines Revolution Nasdaq: APDN Exhibit 99.1 Cell - Free Enzymatic DNA Empowering the Genetic Medicines Revolution Nasdaq: APDN The statements made by Applied DNA in this presentation may be “forward - looking” in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 . Forward - looking statements desc |
|
| April 24, 2024 |
As filed with the Securities and Exchange Commission on April 23, 2024 As filed with the Securities and Exchange Commission on April 23, 2024 Registration No. |
|
| April 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Applied DNA Sciences, Inc. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorp |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commissi |
|
| April 22, 2024 |
Form of Sixth Certificate of Amendment to the Certificate of Incorporation Exhibit 3.1 PROPOSED FORM OF SIXTH CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: FIRST: Article IV of the Certificate of Incorporation, as amended (the “Certificate of Incorporation”), |
|
| April 22, 2024 |
Applied DNA Announces 1-For-20 Reverse Stock Split Exhibit 99.1 Applied DNA Announces 1-For-20 Reverse Stock Split STONY BROOK, N.Y. – April 22, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-20 stock split of its common stock, to be effective as of 12:01 a.m. Eastern Time on Thursday, April 25, 2024. Applied DNA common stock will be |
|
| April 19, 2024 |
Form of Book-Entry Warrant Amendment Exhibit 10.2 AMENDMENT TO WARRANT AGREEMENT THIS AMENDMENT TO WARRANT AGREEMENT (this “Amendment”), dated as of April 16, 2024, is by and between Applied DNA Sciences, Inc., a Delaware corporation (the "Company"), and Equiniti Trust Company, LLC, a New York limited liability trust company (formerly known as American Stock Transfer & Trust Company, LLC), as Warrant Agent (the “Warrant Agent”). WHER |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commissi |
|
| April 19, 2024 |
Form of Purchase Warrant Amendment Exhibit 10.1 AMENDMENT TO COMMON STOCK PURCHASE WARRANT THIS AMENDMENT TO COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of April 16, 2024, is by and between Applied DNA Sciences, Inc., a Delaware corporation (the "Company"), and [●] (the “Holder”). WHEREAS, pursuant to a Placement Agency Agreement, dated January 31, 2024, by and among the Company and Maxim Group, LLC and Securities Pu |
|
| April 16, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commissi |
|
| March 20, 2024 |
Up to 11,288,122 shares of Common Stock underlying the Common Warrants Applied DNA Sciences, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-277832 PROSPECTUS Up to 11,288,122 shares of Common Stock underlying the Common Warrants Applied DNA Sciences, Inc. This prospectus relates to the resale from time to time, by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the caption “Selling Stockholders,” of up to 11,288,122 shares of common stock, |
|
| March 18, 2024 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 March 18, 2024 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 March 18, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed March 12, 2024, as amended File No. 333-277832 Ladies and Gent |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024. As filed with the Securities and Exchange Commission on March 15, 2024. Registration Statement No. 333-277832 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdictio |
|
| March 14, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024. As filed with the Securities and Exchange Commission on March 11, 2024. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdiction of incorporation or org |
|
| March 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) APPLIED DNA SCIENCES, INC. |
|
| March 4, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 12, 2024 |
APDN / Applied DNA Sciences, Inc. / Grossman Bruce - SCHEDULE 13G Passive Investment SC 13G 1 eh24044723313g-adna.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied DNA Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03815U201 (CUSIP Number) February 2, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 8, 2024 |
Lease Renewal Agreement dated January 10, 2024 (Laboratory Lease). Exhibit 10.3 December 18, 2023 Beth Jantzen, CPA Chief Financial Officer Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, NY 11790 Dear Ms. Jantzen, In accordance with your Lease dated February 24, 2023, the Long Island High Technology Incubator, Inc. hereby renews your lease for a period of one year. The Term of the renewal is 2/1/2024 to 1/31/2025. Applied DNA Sciences, Inc. occu |
|
| February 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36745 59-2262718 (State or other jurisdiction of incorporation) (Commis |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 |
|
| February 8, 2024 |
Exhibit 99.1 Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results - Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar 2024, Projects Initial Facility Capacity to Enable up to $15 Million1 of Linea IVT Revenue2 Annually - - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. |
|
| February 1, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| February 1, 2024 |
Form of Private Common Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 1, 2024 |
Exhibit 99.1 Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules STONY BROOK, N.Y., - January 31, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities purchase agreements (SPAs) with certain existing institutional investors (collectively the “Hol |
|
| February 1, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 31, 2024, between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| February 1, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT January 31, 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”),Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $3,437,233.15 of registered and unregistered securities of the Company, including, b |
|
| February 1, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272267 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2023) APPLIED DNA SCIENCES, INC. 3,228,056 Shares of Common Stock Pre-Funded Warrants to Purchase 2,416,005 Shares of Common Stock We are offering 3,228,056 shares of our common stock (the "Shares") at a price of $0.609 per share, to investors pursuant to this prospectus supplement and t |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 APPLIED DN |
|
| January 8, 2024 |
A Next Generation Platform for Genetic Medicine Manufacturing Nasdaq: APDN Exhibit 99.1 A Next Generation Platform for Genetic Medicine Manufacturing Nasdaq: APDN The statements made by Applied DNA in this presentation may be “forward - looking” in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 . Forward - looking statements describe App |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| January 5, 2024 |
Exhibit 10.1 January 3, 2024 ViA EMAIL [email protected] James A. Hayward, Ph.D., Sc.D. President and Chief Executive Officer Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, NY 11790 Re: Voluntary Base Salary Reduction Dear Jim: As you are aware, Applied DNA Sciences, Inc. (the “Company”) is experiencing certain cash flow difficulties. Accordingly, in order to assist the Com |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| January 5, 2024 |
Exhibit 10.2 January 3, 2024 ViA EMAIL [email protected] Ms. Judy Murrah Chief Operating Officer Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, NY 11790 Re: Voluntary Base Salary Reduction Dear Judy: As you are aware, Applied DNA Sciences, Inc. (the “Company”) is experiencing certain cash flow difficulties. Accordingly, in order to assist the Company with this current situati |
|
| December 7, 2023 |
Exhibit 99.1 Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. - December 7, 2023 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for its fourth quarter ended September 30, 2023. “O |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 APPLIED DN |
|
| December 7, 2023 |
Subsidiaries of Applied DNA Sciences, Inc. Exhibit 21.1 SUBSIDIARIES OF APPLIED DNA SCIENCES, INC. Subsidiary State or Country of Incorporation APDN (B.V.I.) Inc. British Virgin Islands Applied DNA Sciences Europe Limited United Kingdom Applied DNA Sciences India Private Limited India LineaRX, Inc. Delaware Applied DNA Clinical Labs LLC Delaware Spindle Biotech, Inc. Canada |
|
| December 6, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| November 7, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| November 7, 2023 |
Exhibit 10.1 APPLIED DNA SCIENCES, INC. Up to $6,397,939 of Common Stock EQUITY DISTRIBUTION AGREEMENT November 7, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC, as exclusive sales agent (the “Agent”), shares of common stock, par v |
|
| November 7, 2023 |
APPLIED DNA SCIENCES, INC. Up to $6,397,939 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-272267 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2023) APPLIED DNA SCIENCES, INC. Up to $6,397,939 Common Stock We have entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Maxim Group LLC, or Maxim Group, relating to shares of our common stock offered by this prospectus supplement and the accompany |
|
| September 20, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| August 10, 2023 |
Exhibit 99.1 Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, N.Y. - August 10, 2023 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fisca |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 App |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| August 8, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| July 13, 2023 |
Exhibit 99.2 ©2023 Applied DNA Sciences, Inc. Applied DNA Acquires Spindle Biotech Better RNA…Faster July 13, 2023 ©2023 Applied DNA Sciences, Inc. Nasdaq: APDN ©2023 Applied DNA Sciences, Inc. The statements made by Applied DNA in this presentation may be “forward - looking” in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| July 13, 2023 |
Exhibit 99.1 Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVTTM Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach - Platform Enables Customers to Manufacture mRNA with Substantial Reduction in dsRNA and Manufacturing Complexities; Integrable into Current mRNA Workflows - - Platform Currently Available Under Early Access Program - STONY BR |
|
| July 13, 2023 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version SHARE PURCHASE AGREEMENT by and among SPINDLE ACQUISITION CORP. SPINDLE BIOTECH INC., THE PERSONS LISTED ON Schedule 1.1, Lai Him Chung and solely for the purpose of Sec |
|
| June 2, 2023 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 June 2, 2023 Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 June 2, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jennie Beysolow Re: Applied DNA Sciences, Inc. Registration Statement on Form S-3 Filed May 30, 2023 File No. 333-272267 Ladies and Gentlemen: Pu |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
Exhibit 4.1 APPLIED DNA SCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ |
|
| May 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Applied DNA Sciences, Inc. |
|
| May 11, 2023 |
Exhibit 99.1 Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update - linearDNA™ Gaining Momentum as a Differentiated DNA Template for mRNA Production, Company Identifies Early Development-Stage Acquisition Target to Potentially Expand Commercial Advantages - - Balance of CY23 Set Up for Multiple Value Inflection Points - - Conference Call/Webcast Scheduled |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numbe |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 Ap |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Number |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| March 28, 2023 |
Form of Restricted Stock Unit Award Agreement EX-10.1 2 tm2310669d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 APPLIED DNA SCIENCES, INC. 2020 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Applied DNA Sciences, Inc. (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”) the number of restricted stock units specified, and on the terms set forth, below in co |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| February 28, 2023 |
Exhibit 10.1 LONG ISLAND HIGH TECHNOLOGY INCUBATOR, INC. LIHTI2 AMENDED AND RESTATED LEASE AGREEMENT This Amended and Restated Lease Agreement ("Lease") made as of the 24th day of February 2023 between Long Island High Technology Incubator, Inc., a not-for-profit education corporation existing under the laws of the State of New York, having its principal place of business at 25 Health Sciences |
|
| February 28, 2023 |
Exhibit 10.2 LONG ISLAND HIGH TECHNOLOGY INCUBATOR, INC. LIHTI1 AMENDED AND RESTATED LEASE AGREEMENT This Amended and Restated Lease Agreement ("Lease") made as of the 24th day of February 2023 between Long Island High Technology Incubator, Inc., a not-for-profit education corporation existing under the laws of the State of New York, having its principal place of business at 25 Health Scienc |
|
| February 9, 2023 |
Exhibit 99.1 Applied DNA Reports First Quarter Fiscal 2023 Financial Results - Total Revenues of $5.3 Million, Up 48% Over FQ4 2022 and 26% Over FQ1 2022, 72% and 74% Reduction in Operating Loss, Respectively - - Included Orders for R&D Quantities of linearDNA™ from New Biopharma Customers - - Maintains Timeline to cGMP Capacity, Initiates Build-out of Cost-Efficient Facility - - Business Update C |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 |
|
| February 9, 2023 |
APDN / Applied DNA Sciences Inc / Grossman Bruce - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Applied DNA Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03815U201 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2023 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File N |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36745 APPLIED DN |
|
| December 14, 2022 |
Exhibit 10.45 Portions of this exhibit have been omitted because the information is both not material and is the type that the Company treats as private or confidential. The omissions have been indicated by bracketed asterisks (?[***]?). ? Contract Number T212206 by and between The City University of New York and Applied DNA Clinical Labs, LLC ? This is a services contract (?Contract? or ?Agreemen |
|
| December 14, 2022 |
Code of Business Conduct and Ethics. Exhibit 14.1 ? CODE OF BUSINESS CONDUCT AND ETHICS 1. General Principles ? The purpose of this code is to describe our standards of ethics and business conduct. ? It is the intent of Applied DNA Sciences, Inc. (the Company) to conduct its business with integrity and ethics which applies to all employees, officers and directors. It is the intent of Applied DNA Sciences, Inc. (the Company) to conduc |
|
| December 14, 2022 |
Exhibit 10.46 ? Portions of this exhibit have been omitted because the information is both not material and is the type that the Company treats as private or confidential. The omissions have been indicated by bracketed asterisks (?[***]?). ? First Amendment to Contract No. T212206 by and between Applied DNA and The City University of New York ? This First Amendment to Contract No. T212206 (?First |
|
| December 14, 2022 |
Exhibit 99.1 Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results - Delivers 17% Revenue Growth Q/Q and 101% Y/Y - - Cash and Cash Equivalents at $15.2 Million - - Company to Hold Conference Call and Webcast Today, Wednesday, December 14, 2022, at 4:30 PM ET - STONY BROOK, N.Y. - December 14, 2022 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (?Applied DNA? or the ?Company?), |
|
| December 14, 2022 |
Exhibit 10.43 ? ? ? ? ? ? ? ? ? Beth Jantzen, CPA February 1, 2022 Chief Financial Officer ? Applied DNA Sciences, Inc. ? 50 Health Sciences Drive ? Stony Brook, NY 11790 ? ? Dear Ms. Jantzen, ? In accordance with your Lease dated June 14, 2013, the Long Island High Technology Incubator, Inc. hereby renews your lease for a period of one year. ? The Term of the renewal is February 1, 2022 to Januar |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 14, 2022 |
Exhibit 10.44 ? ? ? ? ? ? ? Beth Jantzen, CPA February 1, 2022 Chief Financial Officer ? Applied DNA Sciences, Inc. ? 50 Health Sciences Drive ? Stony Brook, NY 11790 ? ? Dear Ms. Jantzen, ? In accordance with your Lease dated November 1, 2015, the Long Island High Technology Incubator, Inc. hereby renews your lease for a period of one year. ? The Term of the renewal is February 1, 2022 to January |
|
| December 14, 2022 |
Exhibit 10.47 ? Portions of this exhibit have been omitted because the information is both not material and is the type that the Company treats as private or confidential. The omissions have been indicated by bracketed asterisks (?[***]?). Second Amendment to Contract No. T212206 by and between Applied DNA and The City University of New York ? This Second Amendment to Contract No. T212206 (?Second |
|
| December 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2022 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| September 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2022 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Nu |
|
| August 11, 2022 |
Exhibit 99.1 Applied DNA Reports Third Quarter Fiscal 2022 Financial Results - Clinical Testing Services Drive Revenue Growth of 153% Year-Over-Year to $4.3 Million - - Post-Quarter Close Cash Balance of $16.8 Million Includes Proceeds from Upsized Public Offering and Warrant Exercises - - Company to Hold Conference Call and Webcast Today, August 11, 2022, at 4:30 PM ET - STONY BROOK, N.Y. ? Augus |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitt |
|
| August 9, 2022 |
EXHIBIT 99.1 Applied DNA Announces Pricing of $12 Million Upsized Public Offering, Priced at a Premium to Market Under Nasdaq Rules STONY BROOK, N.Y., - August 4, 2022 - Applied DNA Sciences, Inc., (NASDAQ: APDN) (the ?Company? or ?Applied DNA?), a leader in polymerase chain reaction ("PCR")-based technologies, today announced the pricing of a public offering of 3,000,000 shares of its common stoc |
|
| August 9, 2022 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between Applied DNA Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set |
|
| August 9, 2022 |
EXHIBIT 4.2 SERIES B COMMON STOCK PURCHASE WARRANT APPLIED DNA SCIENCES, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| August 9, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2022 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| August 9, 2022 |
EXHIBIT 4.1 SERIES A COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| August 9, 2022 |
EXHIBIT 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| August 9, 2022 |
Applied DNA Announces Closing of Upsized $12 Million Public Offering EXHIBIT 99.2 Applied DNA Announces Closing of Upsized $12 Million Public Offering STONY BROOK, N.Y., - August 8, 2022 - Applied DNA Sciences, Inc., (NASDAQ: APDN) (the ?Company? or ?Applied DNA?), a leader in polymerase chain reaction ("PCR")-based technologies, today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock (or common stock equivale |
|
| August 8, 2022 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-266223 and 333-266512 PROSPECTUS Applied DNA Sciences, Inc. $12,000,000 3,000,000 Shares of Common Stock and Accompanying Series A Warrants to Purchase 3,000,000 Shares of Common Stock and Series B Warrants to Purchase 3,000,000 Shares of Common Stock or 3,000,000 Pre-Funded Warrants to Purchase 3,000,000 Shares of Common Stock and Accompanyin |
|
| August 8, 2022 |
EXPLANATORY NOTE On August 8, 2022, the registrant previously filed this prospectus (the ?Original Filing?) with the Securities and Exchange Commission. |
|
| August 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Applied DNA Sciences, Inc. |
|
| August 4, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| August 2, 2022 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 August 2, 2022 CORRESP 1 filename1.htm Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 August 2, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Alyssa Wall Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 Filed July 19, 2022; amended August 1, 20 |
|
| August 2, 2022 |
CORRESP 1 filename1.htm August 2, 2022 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Applied DNA Sciences, Inc. Registration Statement on Form S-1 (Registration No. 333-266223) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best effo |
|
| August 2, 2022 |
Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus Exhibit 99.1 Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus STONY BROOK, N.Y. – August 2, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has initiated analy |
|
| August 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Num |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 1, 2022 |
As filed with the Securities and Exchange Commission on August 1, 2022 As filed with the Securities and Exchange Commission on August 1, 2022 Registration No. |
|
| August 1, 2022 |
EXHIBIT 4.10 SERIES B COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| August 1, 2022 |
EXHIBIT 4.9 SERIES A COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| August 1, 2022 |
EXHIBIT 4.11 PRE-FUNDED COMMON STOCK PURCHASE WARRANT applied dna sciences, inc. Warrant Shares: Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| August 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Applied DNA Sciences, Inc. |
|
| August 1, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted |
|
| August 1, 2022 |
Form of Securities Purchase Agreement Exhibit 10.42 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between Applied DNA Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set |
|
| July 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2022 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| July 27, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266217 PROSPECTUS APPLIED DNA SCIENCES, INC. 1,496,400 SHARES OF COMMON STOCK ISSUED PURSUANT TO THE EXERCISE OF WARRANTS This prospectus relates to the resale by the selling stockholder named herein, including its transferees, pledgees or donees, or their respective successors, of up to 1,496,400 shares (the ?Shares?) of Applied DNA Sciences, |
|
| July 27, 2022 |
©2022 Applied DNA Sciences, Inc. The Future of RNA Therapies Produced with LinearDNA ̿ IVT Templates Exhibit 99.1 ?2022 Applied DNA Sciences, Inc. The Future of RNA Therapies Produced with LinearDNA ? IVT Templates ?2022 Applied DNA Sciences, Inc. Forward Looking Statement 2 The statements made by Applied DNA in this presentation may be ?forward - looking? in nature within the meaning of Section 27 A of the Securities Act of 1933 , Section 21 E of the Securities Exchange Act of 1934 and the Priva |
|
| July 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36745 (Commission File Numb |
|
| July 25, 2022 |
Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 July 25, 2022 CORRESP 1 filename1.htm Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 July 25, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Alyssa Wall Re: Applied DNA Sciences, Inc. Registration Statement on Form S-3 Filed July 19, 2022 File No. 333-266217 La |
|
| July 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Applied DNA Sciences, Inc. |
|
| July 19, 2022 |
As filed with the Securities and Exchange Commission on July 19, 2022 Registration No. |
|
| July 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 APPLIED DNA SCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carr |
|
| July 19, 2022 |
S-3 1 tm2221337d1s3.htm FORM S-3 As filed with the Securities and Exchange Commission on July 19, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APPLIED DNA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation o |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
